Skip to main content

Advertisement

SpringerLink
Log in

Role of intravitreal bevacizumab in the management of Eales’ disease

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose To evaluate the role of intravitreal bevacizumab in the treatment of Eales’ disease. Study design Retrospective, interventional case series. Methods Two patients with proliferative Eales’ disease were managed with an intravitreal injection of bevacizumab (1.25 mg). The presence of persistent retinal neovascularization despite adequate laser photocoagulation caused recurrent episodes of vitreous hemorrhage in the first patient. The second patient had florid retinal and disc neovascularization with a dispersed vitreous bleed, which prevented laser therapy. Both patients were followed up for 6 months. Results Rapid regression of the retinal neovascularization and clearing of the vitreous hemorrhage were observed in both cases following intravitreal bevacizumab therapy, allowing laser photocoagulation. In both patients, the visual acuity improved, and no signs of recurrence were observed 6 months post-treatment. Conclusion Intravitreal bevacizumab injections may be effective as an adjunctive or alternative treatment of retinal neovascularization in Eales’ disease, where inadequate visualization precludes laser photocoagulation. This approach may also be useful in avoiding vitreoretinal surgical intervention in certain cases. Intravitreal bevacizumab was well tolerated by our patients, and no adverse effects were observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611. doi:10.1210/er.2003-0027

    Article  CAS  PubMed  Google Scholar 

  2. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372. doi:10.1016/j.ophtha.2005.11.019

    Article  PubMed  Google Scholar 

  3. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU (2007) Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141–149. doi:10.1097/IAE.0b013e31802eff83

    Article  PubMed  Google Scholar 

  4. Batioğlu F, Astam N, Ozmert E (2008) Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol 28:59–61. doi:10.1007/s10792-007-9105-2

    Article  PubMed  Google Scholar 

  5. Ahmadieh H, Moradian S, Malihi M (2005) Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab. Int Ophthalmol 26:191–193. doi:10.1007/s10792-007-9036-y

    Article  PubMed  Google Scholar 

  6. Haritoglou C, Kook D, Neubauer A et al (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999–1005. doi:10.1097/01.iae.0000247165.38655.bf

    Article  PubMed  Google Scholar 

  7. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113(1695):e1–15

    PubMed  Google Scholar 

  8. Atmaca LS, Idil A, Gunduz K (1993) Visualization of retinal vasculitis in. Eales’ disease. Ocul Immunol Inflamm 1:41–48. doi:10.3109/09273949309086536

    Article  Google Scholar 

  9. Spitznas M, Meyer-Schwickerath G, Stephan B (1975) The clinical picture of Eales’ disease. Graefes Arch Clin Exp Ophthalmol 194:73–85. doi:10.1007/BF00413371

    Article  CAS  Google Scholar 

  10. Adamis PA, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111–118. doi:10.1097/00006982-200502000-00001

    Article  PubMed  Google Scholar 

  11. Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R (2006) Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand 84:834–835. doi:10.1111/j.1600-0420.2006.00779.x

    Article  PubMed  Google Scholar 

  12. Küçükerdönmez C, Akova YA, Yilmaz G (2008) Intravitreal injection of bevacizumab in Eales disease. Ocul Immunol Inflamm 16:63–65. doi:10.1080/09273940801923903

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, 91, Pocket-B, Sukhdev Vihar, New Delhi, 110025, India

    Bhuvan Chanana, Raj Vardhan Azad & Sourabh Patwardhan

Authors
  1. Bhuvan Chanana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raj Vardhan Azad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sourabh Patwardhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bhuvan Chanana.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chanana, B., Azad, R.V. & Patwardhan, S. Role of intravitreal bevacizumab in the management of Eales’ disease. Int Ophthalmol 30, 57–61 (2010). https://doi.org/10.1007/s10792-009-9292-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-009-9292-0

Keywords

Search

Navigation